Put simply, pybit (Python + Bybit) is the official lightweight one-stop-shop module for the Bybit HTTP and WebSocket APIs. Originally created by Verata Veritatis, it's now maintained by Bybit ...

Transform your LogSeq knowledge base into an AI-powered workspace! This MCP server enables Claude to seamlessly interact with your LogSeq graphs. Semantic search over your Logseq graph using local AI ...

General Dynamics said the safety of soldiers 'is, and has always been, our highest priority'. Trials of the Army's troubled Ajax armoured vehicles will resume "cautiously", with the defence minister ...

Eli Lilly LLY0.87%increase; green up pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3B in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

April 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up ‌to $2.3 billion in cash, as the U.S. drugmaker looks to ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax Therapeutics for its clinical-stage myelofibrosis therapy. At the center of the deal ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory achievements, subject to customary conditions and Hart-Scott-Rodino ...

Of Lilly’s six M&A deals so far in 2026, half have been oncology focused. Credit: Jennie Book/Shutterstock.com. Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire ...

Eli Lilly is picking up Ajax Therapeutics and its once-daily oral blood cancer candidate. The deal follows the pharma’s buyouts of ADC specialist CrossBridge Bio and in vivo CAR T company Kelonia ...

Eli Lilly is springing for yet another company acquisition, announcing Monday the purchase of a startup aiming to advance on currently available treatments for a kind of blood cancer. Lilly will shell ...